A blog about chemistry, drug development, science, and technology
Forbes recently had an article about a vaccine from GlaxoSmithKline (GSK) that may protect against many strains of bird flu.
Vaccine May Treat Many Bird Flu Strains - Forbes.com:
The vaccine measurably increased the levels of antibodies in 400 adults after they were given two shots. THe levels were high enough to give presumed protection against the strain of bird flu it was designed to work against. The more promising result is that it may protect against other strains. Other companies such as Novartis and Sanofi-Aventis has also seen cross-protection in their vaccines. What is interesting is the GSK is using a proprietary adjunct which can increase the number of doses by 10-fold. This would be vital if there were an epidemic.
Technorati Tags: avian flu, bird flu, GlaxoSmithKline, H5N1, Novartis, Sanofi-Aventis, vaccine
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.053 seconds